ASD patients at heart

atHeart Medical aims to establish the first transcatheter ASD occluder with a metal-free frame as the new standard of care for atrial septal defects (ASDs).

The reSept™ ASD Occluder

Occluder

MINIMAL FOOTPRINT

With its metal-free frame and minimal footprint, patients have ‘less device’ permanently implanted

heart

Reduce potential complications

Designed to reduce potential complications without limiting future transseptal interventions

Clinical program

The company is enrolling in its ASCENT-ASD Investigational Device Exemption (IDE) trial.

Company overview

Based in Switzerland and the U.S., we have assembled an exceptional team with decades of experience at medical device start-ups and major corporations.

We have initiated the ASCENT-ASD pivotal trial in the United States and internationally to demonstrate the safety and efficacy of our reSept ASD Occluder for treating patients with clinically significant, isolated ASD. Our reSept ASD Occluder has received Investigational Device Exemption approval from the U.S. FDA.

Our company was founded by the Olle Larsson Holding AG (OLH), a Swiss corporate group with a diverse portfolio of companies in medical devices, among other sectors. Our ASD occluder was initially developed by CARAG, a Swiss engineering and consulting firm, also an OLH company.

Guiding Values

Our name embeds our values: in everything we do, we have clinical excellence and patients at heart.

Turning ideas
into innovations

We are problem solvers developing meaningful solutions for unmet clinical needs.

Commitment to
clinical excellence

We work from “the heart” with a primary focus on our patients.

Fast, agile
best practices

We cultivate collaboration and incorporate learnings from experience.